Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular and physiologic mechanisms of drug resistance in cancer: an overview.

Literature DB >> 11831636

Molecular and physiologic mechanisms of drug resistance in cancer: an overview.

R S Kerbel.

Abstract

Entities: Disease

Mesh：

Substances：
Antineoplastic Agents

Year: 2001 PMID： 11831636 DOI： 10.1023/a:1013129128673

Source DB: PubMed Journal: Cancer Metastasis Rev ISSN： 0167-7659 Impact factor: 9.264

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

1. siRNA-mediated down-regulation of P-glycoprotein in a Xenograft tumor model in NOD-SCID mice.

Authors: Meysam Abbasi; Hamidreza Montazeri Aliabadi; Elaine H Moase; Afsaneh Lavasanifar; Kamaljit Kaur; Raymond Lai; Charles Doillon; Hasan Uludağ
Journal: Pharm Res Date: 2011-06-03 Impact factor: 4.200

2. Regulation of tumor angiogenesis by EZH2.

Authors: Chunhua Lu; Hee Dong Han; Lingegowda S Mangala; Rouba Ali-Fehmi; Christopher S Newton; Laurent Ozbun; Guillermo N Armaiz-Pena; Wei Hu; Rebecca L Stone; Adnan Munkarah; Murali K Ravoori; Mian M K Shahzad; Jeong-Won Lee; Edna Mora; Robert R Langley; Amy R Carroll; Koji Matsuo; Whitney A Spannuth; Rosemarie Schmandt; Nicholas B Jennings; Blake W Goodman; Robert B Jaffe; Alpa M Nick; Hye Sun Kim; Eylem Ozturk Guven; Ya-Huey Chen; Long-Yuan Li; Ming-Chuan Hsu; Robert L Coleman; George A Calin; Emir B Denkbas; Jae Yun Lim; Ju-Seog Lee; Vikas Kundra; Michael J Birrer; Mien-Chie Hung; Gabriel Lopez-Berestein; Anil K Sood
Journal: Cancer Cell Date: 2010-08-09 Impact factor: 31.743

3. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.

Authors: Remi Adelaiye; Eric Ciamporcero; Kiersten Marie Miles; Paula Sotomayor; Jonathan Bard; Maria Tsompana; Dylan Conroy; Li Shen; Swathi Ramakrishnan; Sheng-Yu Ku; Ashley Orillion; Joshua Prey; Gerald Fetterly; Michael Buck; Sreenivasulu Chintala; Georg A Bjarnason; Roberto Pili
Journal: Mol Cancer Ther Date: 2014-12-17 Impact factor: 6.261

4. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

Authors: Yu Sun; Judith Campisi; Celestia Higano; Tomasz M Beer; Peggy Porter; Ilsa Coleman; Lawrence True; Peter S Nelson
Journal: Nat Med Date: 2012-09 Impact factor: 53.440

5. Caveolin-1 affects tumor drug resistance in esophageal squamous cell carcinoma by regulating expressions of P-gp and MRP1.

Authors: Song Zhang; Wenbo Cao; Mingjin Yue; Naigang Zheng; Tao Hu; Shengli Yang; Ziming Dong; Shixin Lu; Saijun Mo
Journal: Tumour Biol Date: 2016-01-14

6. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis.

Authors: Ari Hashimoto; Shigeru Hashimoto; Ryo Ando; Kosuke Noda; Eiji Ogawa; Hirokazu Kotani; Mayumi Hirose; Toshi Menju; Masaki Morishige; Toshiaki Manabe; Yoshinobu Toda; Susumu Ishida; Hisataka Sabe
Journal: PLoS One Date: 2011-08-15 Impact factor: 3.240

Molecular and physiologic mechanisms of drug resistance in cancer: an overview.

1. siRNA-mediated down-regulation of P-glycoprotein in a Xenograft tumor model in NOD-SCID mice.

2. Regulation of tumor angiogenesis by EZH2.

3. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.

4. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

5. Caveolin-1 affects tumor drug resistance in esophageal squamous cell carcinoma by regulating expressions of P-gp and MRP1.

6. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis.

Review 7. Tumor refractoriness to anti-VEGF therapy.

8. Trastuzumab induces PUMA-dependent apoptosis and inhibits tumor growth in gastric cancer.

9. Synthesis and Evaluation of New Pyrazoline Derivatives as Potential Anticancer Agents in HepG-2 Cell Line.

10. Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma.